Prognostic value of N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP) was analyzed in patients with multiple myeloma complicated by dialysisdependent renal failure. The prospective study included 20 patients with newly diagnosed multiple myeloma. The concentrations of NT-proBNP were measured before antimyeloma chemotherapy. The median age of the patients was 67 (63-76) years. The median glomerular filtration rate was 4 (4, 5) ml/min/1.73 m2. For overall survival, the area under ROC curve was 0.75 and the cut-off point was 7000 pg/ml. At median follow-up of 17.3 months, the overall survival was 76.6±14.8 and 27.3±13.4% (p=0.02) for cases with NT-proBNP levels below and above the cut-off point, respectively. There were no cases of death due to cardiovascular causes. We concluded that the increase in serum concentration of NT-proBNP>7400 pg/ml is associated with the severity of kidney damage and the risk of non-cardiac mortality.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Luchinin AS, Semochkin SV, Minaeva NV, Pozdeev NM, Paramonov IV. Evolution of Anti-Cancer Treatment and its Impact on Surrogate Prognostic Factors in Multiple Myeloma. Klin. Onkogematol. 2018;11(2):175-181. Russian.
Rekhtina IG, Mendeleeva LP. Current approaches to treating of patients with multiple myeloma with renal failure: questions and proofs. Ter. Arkh. 2017;89(7):112-117. Russian.
Daniels LB, Maisel AS. Natriuretic peptides. J. Am. Coll. Cardiol. 2007;50(25):2357-2368.
Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Bladé J, Comenzo R.L, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Cavo M, Rajkumar SV, Durie BG, San Miguel J. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J. Clin. Oncol. 2010;28(33):4976-4984.
Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
Jimenez-Zepeda VH, Duggan P, Neri P, Rashid-Kolvear F, Tay J, Bahlis NJ. Revised International staging system applied to real world multiple myeloma patients. Clin. Lymphoma Myeloma Leuk. 2016;16(9):511-518.
Kawagoe C, Sato Y, Toida T, Nakagawa H, Yamashita Y, Fukuda A, Iwatsubo S, Fujimoto S. N-terminal-pro-B-typenatriuretic peptide associated with 2-year mortality from both cardiovascular and non-cardiovascular origins in prevalent chronic hemodialysis patients. Ren. Fail. 2018;40(1):127-134.
Khalifeh N, Haider D, Hörl WH. Natriuretic peptides in chronic kidney disease and during renal replacement therapy: an update. J. Investig. Med. 2009;57(1):33-39.
McKie PM, Cataliotti A, Sangaralingham SJ, Ichiki T, Cannone V, Bailey KR, Redfield MM, Rodeheffer RJ, Burnett JC Jr. Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study. Mayo Clin. Proc. 2011;86(12):1154-1160.
Milani P, Vincent Rajkumar S, Merlini G, Kumar S, Gertz MA, Palladini G, Lacy M.Q, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Hwa YL, Gonsalves WI, Zeldenrust SR, Kyle RA, Dispenzieri A. N-terminal fragment of the type-B natriuretic peptide (NTproBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am. J. Hematol. 2016;91(11):1129-1134.
Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, Landaas S, Rouleau JL, Domanski MJ, Hall C, Pfeffer MA, Braunwald E; PEACE Investigators. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J. Am. Coll. Cardiol. 2007;50(3):205-214.
Pavo N, Cho A, Wurm R, Strunk G, Krauth M, Agis H, Hülsmann M. N-terminal B-type natriuretic peptide (NT-proBNP) is associated with disease severity in multiple myeloma. Eur. J. Clin. Invest. 2018;48(4). doi: https://doi.org/10.1111/eci.12905.
Richards AM. N-Terminal B-type Natriuretic Peptide in Heart Failure. Heart Fail Clin. 2018;14(1):27-39.
Yurova E, Semochkin S, Roitman A, Kisliak O. Prognostic value of elevated BNP and NT-proBNP levels in elderly patients with multiple myeloma and concomitant chronic heart failure. Haematologica. 2011;96(Suppl. 2):531-532.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 167, No. 2, pp. 228-232, February, 2019
Rights and permissions
About this article
Cite this article
Semochkin, S.V., Misyurina, E.N., Zhelnova, E.I. et al. N-Terminal Fragment of Brain-Type Natriuretic Peptide (NT-proBNP) as a Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma Complicated by Dialysis-Dependent Renal Failure. Bull Exp Biol Med 167, 267–271 (2019). https://doi.org/10.1007/s10517-019-04506-z
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-019-04506-z